Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2532-7151
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees19
Next Earnings Date11/21/2019 (Confirmed)
OptionableNot Optionable
Entera Bio (NASDAQ:ENTX) Frequently Asked Questions
What is Entera Bio's stock symbol?
Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."
How were Entera Bio's earnings last quarter?
Entera Bio Ltd (NASDAQ:ENTX) announced its quarterly earnings results on Tuesday, August, 20th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.16. The company earned ($0.07) million during the quarter. View Entera Bio's Earnings History.
When is Entera Bio's next earnings date?
How can I listen to Entera Bio's earnings call?
Entera Bio will be holding an earnings conference call on Thursday, November 21st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for ENTX?
1 analysts have issued 1 year price objectives for Entera Bio's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Entera Bio's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 223.9% from the stock's current price. View Analyst Price Targets for Entera Bio.
What is the consensus analysts' recommendation for Entera Bio?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Entera Bio.
Has Entera Bio been receiving favorable news coverage?
Headlines about ENTX stock have trended somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Entera Bio earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Entera Bio.
Are investors shorting Entera Bio?
Entera Bio saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,100 shares, an increase of 175.0% from the September 30th total of 400 shares. Based on an average daily trading volume, of 4,500 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company's stock are short sold. View Entera Bio's Current Options Chain.
Who are some of Entera Bio's key competitors?
Some companies that are related to Entera Bio include Fennec Pharmaceuticals (FENC), Acorda Therapeutics (ACOR), Novavax (NVAX), Axcella Health (AXLA), Erytech Pharma (ERYP), Polarityte (PTE), Brainstorm Cell Therapeutics (BCLI), Adaptimmune Therapeutics (ADAP), Champions Oncology (CSBR), Idera Pharmaceuticals (IDRA), Cidara Therapeutics (CDTX), Genocea Biosciences (GNCA), Neon Therapeutics (NTGN), Applied Genetic Technologies (AGTC) and Pluristem Therapeutics (PSTI).
What other stocks do shareholders of Entera Bio own?
Who are Entera Bio's key executives?
Entera Bio's management team includes the folowing people:
- Dr. Phillip Schwartz Ph.D., CEO & Director (Age 57)
- Dr. Hillel Galitzer, Chief Operating Officer (Age 41)
- Dr. Roger J. Garceau, Chief Devel. Advisor & Director (Age 65)
- Dr. Arthur C. Santora II, Chief Medical Officer
When did Entera Bio IPO?
(ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.
How do I buy shares of Entera Bio?
Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Entera Bio's stock price today?
One share of ENTX stock can currently be purchased for approximately $2.47.
How big of a company is Entera Bio?
What is Entera Bio's official website?
How can I contact Entera Bio?
Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at 972-2532-7151 or via email at [email protected]
MarketBeat Community Rating for Entera Bio (NASDAQ ENTX)
MarketBeat's community ratings are surveys of what our community members think about Entera Bio and other stocks. Vote "Outperform" if you believe ENTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
